Biomarkers and Targeted Drug Therapy

Tuesday, 09 March 2010 14:42

Companion Diagnostics uses molecular diagnostic tests to evaluate ‘biomarkers' associated with a specific drug. The drug may target a certain biomarker or a genetic mutation that may be associated with the patient's response to a specific drug. Whereas, pharmacogenetics associates drug interaction with a specific genotype and, thereby, impacts treatment outcomes.

The following companion biomarkers are available at MPLN.

Tradename	Generic Name	Biomarker	Method	Indication
Campath® Gleevec® Gleevec Gleevec Hydrea® Mylotarg® Ontak® Revlimid® Rituxan® Soloris® Tasigna Vesanoid®	Alemtuzumab Imanitib Imanitib Imanitib Hydroxyurea Gentuzumab denileukin diftitox Lenolidomide Rituximab Eculizumab Nilotinib Tretinoin (ATRA)	CD52 BCR/ABL ABL Mutation C-kit (CD117) JAK2 CD33 CD25 deletion 5q31 CD20 FLAER ABL Mutation PML/RARA	Flow Cytometry PCR, FISH PCR IHC PCR Flow Cytometry Flow Cytometry FISH EGR1 Flow Cytometry Flow Cytometry PCR FISH	CLL CML CML GIST MPN AML TCL MDS NHL, CLL PNH CML APL
Camptosar® Erbitux®, Vectibix® Herceptin®	Irrenotecan cetuximab, panitumumab Trastuzumab	UGT1A1 KRAS, BRAF HER2/neu	Invader assay PCR FISH, IHC	Colorectal Cancer Colorectal Cancer Breast Cancer
Coumadin®	Warfarin	CYP2C9, VKORC1	NAT	Warfarin sensitivity